Nura Bio Expands Leadership Team with C-Suite Appointments

Nura Bio, Inc., a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, announced the appointments of Lahar Mehta, M.D. as Chief Medical Officer, and Scott Greenberg as Chief Business Officer. Dr. Mehta and Mr. Greenberg will play key roles as Nura Bio builds a clinical pipeline across a broad range of neurological diseases.

“At Nura Bio, we have made significant progress in developing our company and pipeline,” said Shilpa Sambashivan, Ph.D., Nura Bio CEO. “We are delighted to have Lahar and Scott join our team as we enter the company’s next phase of expansion and clinical development. They will both play critical roles as we evaluate our lead SARM1 inhibitor, NB-4746, in a patient population while continuing to advance our promising preclinical pipeline.”